Infliximab Effects Compared to Conventional Therapy in the Management of Retinal Vasculitis in Behçet Disease

Khalid F. Tabbara, Amal I. Al-Hemidan

Research output: Contribution to journalArticle

Abstract

Purpose: To assess the outcome of retinal vasculitis in patients with Behçet disease treated with infliximab compared to treatment with conventional therapy. Design: Nonrandomized, retrospective comparative clinical study. Methods: Patients with Behçet disease with all four major criteria were included in this study. Patients had recurrent episodes of uveitis and retinal vasculitis. Thirty-three patients (Group 1) were treated with oral prednisone, cyclosporine, and azathioprine or methotrexate for a minimum period of three months. Ten patients (Group 2) who failed to respond to conventional therapy were given infliximab at a dose of 5 mg/kg in a single intravenous infusion on day 1 and every two weeks for a total of six doses. Patients were given the same treatment during each subsequent relapse. The main outcome measures were the number of relapses, visual outcome, and ocular complications. Results: The mean follow-up period was 36 months in Group 1 and 30 months in Group 2. The mean number of relapses was significantly reduced and the duration of remission was longer in the infliximab therapy group compared to conventional therapy group (P <.0001). The visual acuity at 24 months follow-up was significantly better in patients treated with infliximab (Group 2) when compared to conventional therapy (Group 1) (P = .0059). Conclusions: Patients with Behçet disease had significant decrease in inflammation, improvement of visual acuity, and reduced ocular complications following infliximab when compared to conventional therapy. The number of relapses was less in the infliximab treatment group than the conventional therapy group.

Original languageEnglish (US)
JournalAmerican Journal of Ophthalmology
Volume146
Issue number6
DOIs
StatePublished - Dec 2008

Fingerprint

Retinal Vasculitis
Group Psychotherapy
Recurrence
Therapeutics
Visual Acuity
Infliximab
Uveitis
Azathioprine
Prednisone
Intravenous Infusions
Methotrexate
Cyclosporine
Outcome Assessment (Health Care)
Inflammation

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Infliximab Effects Compared to Conventional Therapy in the Management of Retinal Vasculitis in Behçet Disease. / Tabbara, Khalid F.; Al-Hemidan, Amal I.

In: American Journal of Ophthalmology, Vol. 146, No. 6, 12.2008.

Research output: Contribution to journalArticle

@article{645e4db1532e466493ea43447e841550,
title = "Infliximab Effects Compared to Conventional Therapy in the Management of Retinal Vasculitis in Beh{\cc}et Disease",
abstract = "Purpose: To assess the outcome of retinal vasculitis in patients with Beh{\cc}et disease treated with infliximab compared to treatment with conventional therapy. Design: Nonrandomized, retrospective comparative clinical study. Methods: Patients with Beh{\cc}et disease with all four major criteria were included in this study. Patients had recurrent episodes of uveitis and retinal vasculitis. Thirty-three patients (Group 1) were treated with oral prednisone, cyclosporine, and azathioprine or methotrexate for a minimum period of three months. Ten patients (Group 2) who failed to respond to conventional therapy were given infliximab at a dose of 5 mg/kg in a single intravenous infusion on day 1 and every two weeks for a total of six doses. Patients were given the same treatment during each subsequent relapse. The main outcome measures were the number of relapses, visual outcome, and ocular complications. Results: The mean follow-up period was 36 months in Group 1 and 30 months in Group 2. The mean number of relapses was significantly reduced and the duration of remission was longer in the infliximab therapy group compared to conventional therapy group (P <.0001). The visual acuity at 24 months follow-up was significantly better in patients treated with infliximab (Group 2) when compared to conventional therapy (Group 1) (P = .0059). Conclusions: Patients with Beh{\cc}et disease had significant decrease in inflammation, improvement of visual acuity, and reduced ocular complications following infliximab when compared to conventional therapy. The number of relapses was less in the infliximab treatment group than the conventional therapy group.",
author = "Tabbara, {Khalid F.} and Al-Hemidan, {Amal I.}",
year = "2008",
month = "12",
doi = "10.1016/j.ajo.2008.09.010",
language = "English (US)",
volume = "146",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Infliximab Effects Compared to Conventional Therapy in the Management of Retinal Vasculitis in Behçet Disease

AU - Tabbara, Khalid F.

AU - Al-Hemidan, Amal I.

PY - 2008/12

Y1 - 2008/12

N2 - Purpose: To assess the outcome of retinal vasculitis in patients with Behçet disease treated with infliximab compared to treatment with conventional therapy. Design: Nonrandomized, retrospective comparative clinical study. Methods: Patients with Behçet disease with all four major criteria were included in this study. Patients had recurrent episodes of uveitis and retinal vasculitis. Thirty-three patients (Group 1) were treated with oral prednisone, cyclosporine, and azathioprine or methotrexate for a minimum period of three months. Ten patients (Group 2) who failed to respond to conventional therapy were given infliximab at a dose of 5 mg/kg in a single intravenous infusion on day 1 and every two weeks for a total of six doses. Patients were given the same treatment during each subsequent relapse. The main outcome measures were the number of relapses, visual outcome, and ocular complications. Results: The mean follow-up period was 36 months in Group 1 and 30 months in Group 2. The mean number of relapses was significantly reduced and the duration of remission was longer in the infliximab therapy group compared to conventional therapy group (P <.0001). The visual acuity at 24 months follow-up was significantly better in patients treated with infliximab (Group 2) when compared to conventional therapy (Group 1) (P = .0059). Conclusions: Patients with Behçet disease had significant decrease in inflammation, improvement of visual acuity, and reduced ocular complications following infliximab when compared to conventional therapy. The number of relapses was less in the infliximab treatment group than the conventional therapy group.

AB - Purpose: To assess the outcome of retinal vasculitis in patients with Behçet disease treated with infliximab compared to treatment with conventional therapy. Design: Nonrandomized, retrospective comparative clinical study. Methods: Patients with Behçet disease with all four major criteria were included in this study. Patients had recurrent episodes of uveitis and retinal vasculitis. Thirty-three patients (Group 1) were treated with oral prednisone, cyclosporine, and azathioprine or methotrexate for a minimum period of three months. Ten patients (Group 2) who failed to respond to conventional therapy were given infliximab at a dose of 5 mg/kg in a single intravenous infusion on day 1 and every two weeks for a total of six doses. Patients were given the same treatment during each subsequent relapse. The main outcome measures were the number of relapses, visual outcome, and ocular complications. Results: The mean follow-up period was 36 months in Group 1 and 30 months in Group 2. The mean number of relapses was significantly reduced and the duration of remission was longer in the infliximab therapy group compared to conventional therapy group (P <.0001). The visual acuity at 24 months follow-up was significantly better in patients treated with infliximab (Group 2) when compared to conventional therapy (Group 1) (P = .0059). Conclusions: Patients with Behçet disease had significant decrease in inflammation, improvement of visual acuity, and reduced ocular complications following infliximab when compared to conventional therapy. The number of relapses was less in the infliximab treatment group than the conventional therapy group.

UR - http://www.scopus.com/inward/record.url?scp=56249116919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56249116919&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2008.09.010

DO - 10.1016/j.ajo.2008.09.010

M3 - Article

C2 - 18929351

AN - SCOPUS:56249116919

VL - 146

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 6

ER -